Thus, prompted by the therapeutic potential of iNKT cells, and especially by the possibility to expand and boost them through triggering their endogenous TCR, we here tested the feasibility of arming iNKT cells with CARs directed against two important MM-associated antigens, CD38- and the B cell maturation antigen (BCMA). Here, CD38 is linked to Miyoshi myopathy.